Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

NCT02218489 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Blepharitis

Interventions

DRUG: KPI-121
DRUG: Vehicle

Sponsor

Kala Pharmaceuticals, Inc.